Compare Abeona Therapeutics Inc (ABEO) vs LYFT Inc (LYFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs LYFT Inc — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while LYFT Inc trades at $15.02 (market cap $5.86B). The key difference: LYFT Inc is far larger — about 15.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | LYFT | |
|---|---|---|
Market Cap | $373.32M | $5.86B |
Sector | Health | Industrials |
52-Week High | $7.23 | $24.57 |
52-Week Low | $4.17 | $12.65 |
Enterprise Value | $228.22M | $5.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Lyft trades at $15.44, up 0.46% today, with a bullish technical signal from moving averages and oscillators. The company shows strong profitability with 43.82% net income margin and robust cash flow generation of $1.17B from operations in 2025. Recent management changes include the appointment of Senthil Padmanabhan as CTO effective July 2026, signaling continued operational focus.
Lyft presents an attractive valuation with P/E of 2.25 and P/S of 0.97, trading below the $18.25 consensus price target. However, mixed earnings performance and competitive pressures from Uber require monitoring. The stock offers upside potential but faces execution risks in the evolving ridesharing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
